Acta Scientific Cardiovascular System

Research Article Volume 1 Issue 5

Echocardiographic Abnormalities in Systemic Lupus Erythematosus and its Association with Anticardiolipin Antibodies and Serum Lipids

Manish Juneja1*, Ganpat Devpura2, Renu Sehgal3 and Harshawardhan Dhanraj Ramteke4

1DM (Cardiology), Director, Senior Consultant and Interventional Cardiologist, Rhythm Heart and Critical Care, Nagpur, India
2Professor, Department of Medicine, SMS Medical College and Hospital, Jaipur, India
3Senior Professor and Unit Head, Incharge Department of Rheumatology Clinic, Department of Medicine, SMS Medical College and Hospital, Jaipur, India
4MBBS, Intern, Department of Cardiology, Rhythm Heart and Critical Care, Nagpur and MBBS (2018), School of International Education, Anhui Medical University, Hefei, China

*Corresponding Author: Manish Juneja, DM (Cardiology), Director, Senior Consultant and Interventional Cardiologist, Rhythm Heart and Critical Care, Nagpur, India.

Received: August 18, 2022; Published: September 19, 2022



Background: Systemic Lupus Erythematous (SLE) is an autoimmune disease damaging to organs, tissues and cells mediated by antibodies and immune complexes. The higher occurrence of SLE in females may be because of hormonal changes and effects. Due to lack of awareness, many women undergo screening during the fifth decade of their life and may be diagnosed to have SLE. One of the many possible reasons could be late diagnosis, referral bias, optimal health care facilities, tuberculosis and predisposing genetic factors. Leading causes of early mortality and poor prognosis are because of disease activity and autoimmune infections. Whereas, later mortality is due to cardiovascular disease. Echocardiography to assess cardiac function has been a great tool of use. With use of Echocardiography, patients with SLE can be monitored for cardiac anomalies. Many studies in the past have suggested that increasing prevalence of dyslipidaemia in patients having SLE and their association with atherosclerotic cardiovascular disease, which leads to mortality. Dyslipidaemia is seen to be modifiable risk for cardiovascular diseases, but has been a great scope of research in patients having SLE.

Aim: To study the echocardiographic abnormalities in patients having SLE. Furthermore, association of these findings with anticardiolipin antibodies. In the end, learning the association of the results with serum lipids.

Methods: An observational, Randomised, cross sectional study was conducted with 40 patients diagnosed with SLE according to modified ACR criteria. In the chosen population, 2D Echo findings, anticardiolipin antibodies and lipid profile was studied in the under criteria of inclusion and exclusion on the certain criteria.

Results: The demography of patients included in study were in the ratio of 1:7, meaning 5 males and 35 females. The mean age of the male patients was 30 ± 14.13 years, where as that of females were 29.11 ± 9.57 years. The mean duration of the disease was found to be 2.19 ± 1.99 years, thus concludes that majority of the patients had less than 2 years of disease duration.

Out of the 40 patients, 30 patients had abnormal echocardiographic study, which was categorised into pericardial, myocardial and valvular. On categorisation, it was found that 6 patients had pericardial involvement likely pericardial effusion, 13 patients had myocardial involvement like left ventricular diastolic dysfunction (LVDD) and left ventricular hypertrophy (LVH). 23 patients were reported having valvular regurgitation or thickenings. On comparing the echo findings of males and females, there was no statistically significant difference between males and females. In addition, there was no significant difference in echo with regard to duration of disease. Anticardiolipin antibody was found positive only in 6 patients with the distribution of IgG of 12.5% and IgM of 2.5%. Thus, these findings of anticardiolipin did not implicate the positive complications of SLE. It was also reported that 24 out of 40 patients had abnormal serum lipid values. Serum triglycerides were high in 21 of 40 patients, which showed no significant correlation between TG’s and echocardiographic abnormalities. High cholesterol levels were noted in 4 out of 40 patients and showed no significant correlation between TC’s and echocardiographic abnormalities. 1 patient had very high LDL-C levels, whereas 39 patients had normal ranged values. Out of the lipid profiles mean values, TGs showed abnormally high of 172.45 ± 61.41 mg/dl. Thus, there was no statistically significant and correlation between pericardial, Valvular and Myocardial abnormalities in the studied patients.

Discussion: In the study conducted we could find that valvular incompetence as most common form of valvular involvement. Furthermore, we could find that, myocardial abnormality to be second biggest factor for cardiac involvement of SLE. There was no statistical significance between echo findings and the anticardiolipin antibodies in the give IgG and IgM. Thus, it could not positively implicate the echocardiological manifestations. The most common abnormality was found to be was high serum triglycerides. Furthermore, we also found that there was no significantly correlation between high serum lipids and echocardiographic findings of the pericardial, myocardial and valvular in the 40 cases of SLE.

Conclusion: Most of the SLE patients associated with cardiac disease had no symptoms of cardiac disease. Thus, a high degree of suspension can be there to rule out the cases of SLE with cardiac abnormalities. Routine checks up or screening for cardiac diseases during the SLE to diagnose the cardiac abnormalities. Thus, diagnostic tool for such cases can be Transthoracic 2D echo can help to rule out the causes of cardiac cases. In the screened cases, high possibility of valvular associated abnormalities was indicated. To conclude, prevalence of SLE can be significantly reduced by routine cardiac examination and modify the lifestyle or proper medical management to prevent aggravated response of SLE.

Keywords: Systemic Lupus Erythematous (SLE); Serum Lipids; Dyslipidaemia



  1. Choi J., et al. “The pathogenesis of systemic lupus erythematosus-an update”. Current Opinion Immunology6 (2012): 651-657.
  2. Haikel KAB and Tulaihi BA. “Awareness of Systemic Lupus Erythematosus among Primary Health Care Patients in Riyadh, Saudi Arabia”. Open Access Macedonian Journal of Medical Sciences 12 (2018): 2386-2392.
  3. Bin Haikel KA and Al Tulaihi B. “Awareness of systemic lupus erythematosus among primary health care patients in Riyadh, Saudi Arabia”. Saudi Medicine Journal2 (2019): 177-182.
  4. Malaviya AN., et al. “Prevalence of systemic lupus erythematosus in India”. Lupus2 (1993): 115-118.
  5. Malaviya AN., et al. “Systemic lupus erythematosus in India”. Lupus9 (1997): 690-700.
  6. Rees F., et al. “The incidence and prevalence of systemic lupus erythematosus in the UK, 1999-2012”. Annals of the Rheumatic Diseases1 (2016): 136-141.
  7. Tapani Helve. “Prevalence and Mortality Rates of Systemic Lupus Erythematosus and Causes of Death in SLE Patients in Finland”. Scandinavian Journal of Rheumatology 14 (1985): 43-46.
  8. Izmirly PM., et al. “Prevalence of Systemic Lupus Erythematosus in the United States: Estimates From a Meta-Analysis of the Centers for Disease Control and Prevention National Lupus Registries”. Arthritis and Rheumatology6 (2021): 991-996.
  9. Seid A and Metaferia Y. “Factors associated with treatment delay among newly diagnosed tuberculosis patients in Dessie city and surroundings, Northern Central Ethiopia: a cross-sectional study”. BMC Public Health1 (2018): 931.
  10. Bharath G., et al. “Mortality in systemic lupus erythematosus at a teaching hospital in India: A 5-year retrospective study”. Journal of Family Medicine and Primary Care7 (2019): 2511-2515.
  11. Cojocaru M., et al. “Manifestations of systemic lupus erythematosus”. Maedica (Bucur) 4 (2011): 330-336.
  12. Emorinken A., et al. “Clinical and laboratory profile of systemic lupus erythematosus patients at a rural tertiary centre in South-South Nigeria: experience from a new rheumatology clinic”. Reumatologia 6 (2021): 402-410.
  13. Tan EM., et al. “The 1982 revised criteria for the classification of systemic lupus erythematosus”. Arthritis and Rheumatology11 (1982): 1271-1277.
  14. Lee Y and Siddiqui WJ. “Cholesterol Levels”. Updated 2021 Jul 26. In: StatPearls Internet. Treasure Island (FL): StatPearls Publishing; 2022 Jan.
  15. Moulton VR., et al. “Pathogenesis of Human Systemic Lupus Erythematosus: A Cellular Perspective”. Trends in Molecular Medicine7 (2017): 615-635.
  16. Hong J., et al. “Accelerated atherosclerosis in patients with chronic inflammatory rheumatologic conditions”. International Journal of Clinical Rheumatology 5 (2015): 365-381.
  17. Dubey P., et al. “Development and Evaluation of Active Case Detection Methods to Support Visceral Leishmaniasis Elimination in India”. Frontiers in Cellular and Infection Microbiology 11 (2021): 648903.
  18. Ruiz D., et al. “Antiphospholipid Antibodies and Heart Valve Disease in Systemic Lupus Erythematosus”. American Journal of the Medical Sciences 3 (2018): 293-298.
  19. Watad A., et al. “The association between systemic lupus erythematosus and valvular heart disease: an extensive data analysis”. European Journal of Clinical Investigation 5 (2017): 366-371.
  20. Vivero F., et al. “Prevalence and predictors of valvular heart disease in patients with systemic lupus erythematosus”. Autoimmune Review12 (2016): 1134-1140.
  21. Mohamed AAA., et al. “Cardiac Manifestations in Systemic Lupus Erythematosus: Clinical Correlates of Subclinical Echocardiographic Features”. Biomed Research International 2019 (2019): 2437105.
  22. Bouma W., et al. “Mitral valve surgery for mitral regurgitation caused by Libman-Sacks endocarditis: a report of four cases and a systematic review of the literature”. Journal of Cardiothoracular Surgery 5 (2010): 13.
  23. Gabrielli F., et al. “Cardiac valve involvement in systemic lupus erythematosus and primary antiphospholipid syndrome: lack of correlation with antiphospholipid antibodies”. International Journal of Cardiology 2 (1995): 117-126.
  24. Rosenkranz S., et al. “Left ventricular heart failure and pulmonary hypertension”. European Heart Journal12 (2016): 942-954.
  25. Kreps A., et al. “Cardiac Manifestations in Systemic Lupus Erythematosus: A Case Report and Review of the Literature”. American Journal of Medical Case Reports 9 (2018): 180-183.
  26. Ünlü O., et al. “The clinical significance of antiphospholipid antibodies in systemic lupus erythematosus”. European Journal of Rheumatology2 (2016): 75-84.
  27. Ramos-Casals M., et al. “Hypocomplementemia in systemic lupus erythematosus and primary antiphospholipid syndrome: prevalence and clinical significance in 667 patients”. Lupus10 (2004): 777-783.
  28. Spegiorin LC., et al. “Prevalence of anticardiolipin antibodies in pregnancies with history of repeated miscarriages”. Open Rheumatology Journal 4 (2010): 28-30.
  29. Bertolaccini ML., et al. “The value of IgA antiphospholipid testing for diagnosis of antiphospholipid (Hughes) syndrome in systemic lupus erythematosus”. Journal of Rheumatology12 (2001): 2637-2643.
  30. Koniari I., et al. “Antiphospholipid syndrome; its implication in cardiovascular diseases: a review”. Journal of Cardiothoracic Surgery 5 (2010): 101.
  31. A Tincani., et al. “Heart involvement in systemic lupus erythematosus, anti-phospholipid syndrome and neonatal lupus”. Rheumatology 4 (2006): iv8-iv13.
  32. Perez-Villa F., et al. “Severe valvular regurgitation and antiphospholipid antibodies in systemic lupus erythematosus: a prospective, long-term, followup study”. Arthritis and Rheumatology3 (2005): 460-467.
  33. Metz D., et al. “Prevalence of valvular involvement in systemic lupus erythematosus and association with antiphospholipid syndrome: a matched echocardiographic study”. Cardiology2 (1994): 129-136.


Citation: Manish Juneja., et al. “Echocardiographic Abnormalities in Systemic Lupus Erythematosus and its Association with Anticardiolipin Antibodies and Serum Lipids". Acta Scientific Cardiovascular System 1.5 (2022): 03-18.

News and Events

  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is June 25, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue"
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US